ArticleAnnals of cardiothoracic surgery2026
Transaxillary minimally invasive mitral valve surgery: early and mid-term outcomes in 763 patients.
Article in Annals of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The transaxillary (TAxA) approach has been developed as a simplified direct-vision minimally invasive access for heart valve surgery. We report a large single-center cohort of patients undergoing TAxA minimally invasive mitral valve surgery and evaluate early safety, procedural efficacy, recovery and mid-term outcomes. Methods: Consecutive patients who underwent TAxA mitral valve surgery at the University Hospital of Marche, Ancona, Italy, between January 2017 and April 2026 were included. Mitral repair or replacement procedures were considered with or without concomitant tricuspid valve repair, atrial fibrillation ablation or left atrial appendage occlusion. Early outcomes were analyzed in the overall cohort. Mid-term survival and reoperation were assessed in patients undergoing repair for degenerative mitral regurgitation. Results: The study included 763 patients. Mitral valve repair was performed in 640 patients and replacement in 123. The repair rate was 89% in patients with mitral regurgitation and 92% in patients with degenerative mitral regurgitation. Concomitant tricuspid repair, atrial fibrillation ablation and left atrial appendage occlusion were performed in 17%, 5% and 10% of patients, respectively. Mean cardiopulmonary bypass and cross-clamp times were 103 and 63 minutes. Thirty-day mortality was 0.4%, stroke or transient ischemic attack occurred in 0.7%, and conversion to sternotomy was required in 0.7%; no conversion was due to poor exposure. Median ventilation time was 2 [interquartile range (IQR), 0-6] hours, 54% of patients were extubated in theatre and 80% were extubated within 6 hours. Median intensive care unit and hospital stays were 24 (IQR, 22-48) hours and 7 (IQR, 6-9) days. In the degenerative repair cohort, Kaplan-Meier survival was 97.0% at 5 years, and cumulative incidence of reoperation was 4.3% at 5 years. Conclusions: In this large contemporary experience, TAxA minimally invasive mitral valve surgery was associated with low early mortality and morbidity, reasonable operative times, frequent ultra fast-track extubation, and satisfactory mid-term results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.